Literature DB >> 12706657

Aberrant vascular architecture in tumors and its importance in drug-based therapies.

Lance L Munn1.   

Abstract

The vasculature is not simply a collection of hollow tubes through which blood flows - it is an organ in its own right, consisting of several cell types organized in a specific manner, and it mediates many unique biological and physiological functions such as selective filtration and angiogenesis. In tumors, blood vessels have structural and functional abnormalities that, to date, have generally hindered conventional therapies: the malformed networks make it difficult to deliver drugs uniformly to all cancer cells. Furthermore, flow in these vessels is chaotic, with intermittent stagnation followed by high-flow or even flow reversal in isolated segments. Cancer cells in stagnated or low-flow regions will receive suboptimal drug levels during chemotherapy. However, as more is learned about the formation of tumor vasculature and how it differs from that in normal tissue, more effective and directed therapies to fight cancer might be developed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12706657     DOI: 10.1016/s1359-6446(03)02686-2

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  26 in total

1.  Breast cancer cell-derived matrix supports vascular morphogenesis.

Authors:  Abigail C Hielscher; Connie Qiu; Sharon Gerecht
Journal:  Am J Physiol Cell Physiol       Date:  2012-01-25       Impact factor: 4.249

Review 2.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

3.  Response-Derived Input Function Estimation for Dynamic Contrast-Enhanced MRI Demonstrated by Anti-DLL4 Treatment in a Murine U87 Xenograft Model.

Authors:  Matthew D Silva; Brittany Yerby; Jodi Moriguchi; Albert Gomez; H Toni Jun; Angela Coxon; Sharon E Ungersma
Journal:  Mol Imaging Biol       Date:  2017-10       Impact factor: 3.488

Review 4.  Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer.

Authors:  Daniel C Julien; Steven Behnke; Guankui Wang; Gordon K Murdoch; Rodney A Hill
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

Review 5.  Cancer metabolism gets physical.

Authors:  Peter DelNero; Benjamin D Hopkins; Lewis C Cantley; Claudia Fischbach
Journal:  Sci Transl Med       Date:  2018-05-23       Impact factor: 17.956

Review 6.  Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.

Authors:  Su-Tang Lo; Amit Kumar; Jer-Tsong Hsieh; Xiankai Sun
Journal:  Mol Pharm       Date:  2013-01-24       Impact factor: 4.939

Review 7.  Intravital imaging of CD8+ T cell function in cancer.

Authors:  Thorsten R Mempel; Christian A Bauer
Journal:  Clin Exp Metastasis       Date:  2008-07-30       Impact factor: 5.150

8.  Automating tumor classification with pixel-by-pixel contrast-enhanced ultrasound perfusion kinetics.

Authors:  Casey N Ta; Yuko Kono; Christopher V Barback; Robert F Mattrey; Andrew C Kummel
Journal:  J Vac Sci Technol B Nanotechnol Microelectron       Date:  2012-03-22

9.  Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.

Authors:  Jeff S Isenberg; Fuminori Hyodo; Lisa A Ridnour; Caitlin S Shannon; David A Wink; Murali C Krishna; David D Roberts
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

10.  Implantable tissue isolation chambers for analyzing tumor dynamics in vivo.

Authors:  Gabriel Gruionu; Despina Bazou; Nir Maimon; Mara Onita-Lenco; Lucian G Gruionu; Peigen Huang; Lance L Munn
Journal:  Lab Chip       Date:  2016-04-29       Impact factor: 6.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.